[go: up one dir, main page]

MXPA02009210A - Modificacion amorfa de torasemida. - Google Patents

Modificacion amorfa de torasemida.

Info

Publication number
MXPA02009210A
MXPA02009210A MXPA02009210A MXPA02009210A MXPA02009210A MX PA02009210 A MXPA02009210 A MX PA02009210A MX PA02009210 A MXPA02009210 A MX PA02009210A MX PA02009210 A MXPA02009210 A MX PA02009210A MX PA02009210 A MXPA02009210 A MX PA02009210A
Authority
MX
Mexico
Prior art keywords
torasemide modification
amorphous torasemide
amorphous
modification
preparation
Prior art date
Application number
MXPA02009210A
Other languages
English (en)
Inventor
Marijan Tudja
Original Assignee
Pliva D D
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliva D D filed Critical Pliva D D
Publication of MXPA02009210A publication Critical patent/MXPA02009210A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion se relaciona con una modificacion de torasemida amorfa, con un procedimiento para la preparacion de la misma, para su utilizacion como materia prima para la preparacion de sales de torasemida farmaceuticamente aceptables, en formas farmaceuticas que contienen esta modificacion de torasemida amorfa, como asi tambien, con su utilizacion como diuretico.
MXPA02009210A 2000-03-20 2000-05-02 Modificacion amorfa de torasemida. MXPA02009210A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HR20000162A HRP20000162B1 (en) 2000-03-20 2000-03-20 Amorphous torasemide modification
PCT/HR2000/000011 WO2001070694A1 (en) 2000-03-20 2000-05-02 Amorphous torasemide modification

Publications (1)

Publication Number Publication Date
MXPA02009210A true MXPA02009210A (es) 2004-09-06

Family

ID=10947070

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02009210A MXPA02009210A (es) 2000-03-20 2000-05-02 Modificacion amorfa de torasemida.

Country Status (29)

Country Link
US (1) US6767917B1 (es)
EP (1) EP1272470B1 (es)
JP (1) JP2003528083A (es)
KR (1) KR20020093847A (es)
CN (1) CN1211368C (es)
AR (1) AR023788A1 (es)
AT (1) ATE256662T1 (es)
AU (1) AU2000241348A1 (es)
BG (1) BG107208A (es)
BR (1) BR0017175A (es)
CA (1) CA2401908A1 (es)
CZ (1) CZ20023436A3 (es)
DE (1) DE60007360T2 (es)
EA (1) EA004950B1 (es)
EE (1) EE200200534A (es)
ES (1) ES2213006T3 (es)
GE (1) GEP20043300B (es)
HR (1) HRP20000162B1 (es)
HU (1) HUP0300596A3 (es)
IL (1) IL151801A0 (es)
IS (1) IS6551A (es)
MX (1) MXPA02009210A (es)
NO (1) NO20024464L (es)
PL (1) PL357154A1 (es)
PT (1) PT1272470E (es)
SK (1) SK15092002A3 (es)
WO (1) WO2001070694A1 (es)
YU (1) YU70502A (es)
ZA (1) ZA200208309B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI20816A (sl) * 1999-08-11 2002-08-31 Teva Pharmaceutical Industries Ltd. Polimorfi torsemid-a
IN192178B (es) * 2001-08-03 2004-03-06 Ranbaxy Lab
EP1668008A4 (en) 2003-08-28 2009-02-25 Nitromed Inc NITROSED AND NITROSYLATED DIETETIC COMPOUNDS, COMPOSITIONS AND APPLICATION METHODS
AU2006216665A1 (en) 2005-02-24 2006-08-31 Nicox S.A. Nitric oxide enhancing diuretic compounds, compositions and methods of use
CN100421662C (zh) * 2005-11-08 2008-10-01 周卓和 托拉塞米分散片及其制备方法和应用
CN104370805B (zh) * 2013-08-13 2016-09-07 天津汉瑞药业有限公司 托拉塞米化合物
CN105949115A (zh) * 2016-05-26 2016-09-21 南京正科医药股份有限公司 一种新晶型托拉塞米
CN115417810B (zh) * 2022-09-22 2023-10-10 南京正科医药股份有限公司 一种托拉塞米晶型ⅰ的精制方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1477664A (en) 1974-04-17 1977-06-22 Christiaens Sa A Pyridine derivatives
DE3529529A1 (de) * 1985-08-17 1987-02-19 Boehringer Mannheim Gmbh Verfahren zur herstellung einer stabilen modifikation von torasemid
GB8816620D0 (en) 1988-07-13 1988-08-17 Lepetit Spa Rifapentine hydrohalides
ES2150105T3 (es) 1995-02-22 2000-11-16 Aventis Pharma Ltd Piretanida amorfa, polimorfos de piretanida, proceso para su preparacion y su uso.
IN182496B (es) 1996-02-20 1999-04-17 Reddy Research Foundation
HRP980532B1 (en) 1998-10-02 2005-06-30 Pliva Novel crystalline torasemide modification
US5914336A (en) * 1998-06-02 1999-06-22 Boehringer Mannheim Gmbh Method of controlling the serum solubility of orally administered torasemide and composition relating thereto
SI20816A (sl) 1999-08-11 2002-08-31 Teva Pharmaceutical Industries Ltd. Polimorfi torsemid-a

Also Published As

Publication number Publication date
AR023788A1 (es) 2002-09-04
PL357154A1 (en) 2004-07-12
CZ20023436A3 (cs) 2003-03-12
HRP20000162B1 (en) 2004-06-30
CA2401908A1 (en) 2001-09-27
GEP20043300B (en) 2004-02-10
NO20024464L (no) 2002-09-20
JP2003528083A (ja) 2003-09-24
US6767917B1 (en) 2004-07-27
EE200200534A (et) 2004-04-15
CN1452613A (zh) 2003-10-29
IL151801A0 (en) 2003-04-10
AU2000241348A1 (en) 2001-10-03
WO2001070694A1 (en) 2001-09-27
YU70502A (sh) 2006-01-16
HRP20000162A2 (en) 2001-12-31
DE60007360D1 (de) 2004-01-29
ATE256662T1 (de) 2004-01-15
DE60007360T2 (de) 2004-10-07
EP1272470A1 (en) 2003-01-08
EP1272470B1 (en) 2003-12-17
BR0017175A (pt) 2002-12-10
NO20024464D0 (no) 2002-09-18
EA004950B1 (ru) 2004-10-28
BG107208A (bg) 2003-07-31
SK15092002A3 (sk) 2003-05-02
ZA200208309B (en) 2003-10-15
EA200201003A1 (ru) 2003-02-27
HUP0300596A2 (hu) 2003-07-28
WO2001070694A8 (en) 2002-03-21
ES2213006T3 (es) 2004-08-16
IS6551A (is) 2002-09-17
KR20020093847A (ko) 2002-12-16
CN1211368C (zh) 2005-07-20
HUP0300596A3 (en) 2005-08-29
PT1272470E (pt) 2004-05-31

Similar Documents

Publication Publication Date Title
MY152846A (en) New salts of valsartan
MXPA02012795A (es) Carvedilol.
MY134892A (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use
PL392725A1 (pl) Nowe związki pośrednie do syntezy związków triazolopirymidyny oraz sposób ich wytwarzania
MXPA03001431A (es) Polimeros de un analogo de epotilona.
WO2001066534A3 (en) Cyclic and bicyclic diamino histamine-3 receptor antagonists
HUP0302257A3 (en) 4-hydrazino-5-hydroxy-5-pyrazol derivatives, pharmaceutical compositions containing them, process for producing them and their intermediates
BR0013885A (pt) Comprimidos aperfeiçoados
YU69902A (sh) Novi derivati piperazina
YU7804A (sh) Stabilni polimorf flibanserina,postupak za njegovo dobijanje u industrijskim razmerama i njegova primena za pripremanje lekova
WO2001010816A3 (de) Substituierte 2-Dialkylaminoalkylbiphenyl-derivate
YU24001A (sh) Nova kristalna modifikacija torasemida
YU70502A (sh) Amorfna modifikacija torasemida
WO2001049654A3 (de) Substituierte aminomethyl-phenyl-cyclohexanderivate
AP2002002679A0 (en) Novel polymorph V of torasemide.
BR0114380A (pt) Derivados-1-aminobutan-3-ol-substituìdos
FR2796641B1 (fr) Nouveau procede de preparation de composes benzoperhydroisoindole
WO2001049651A3 (de) Aminomethyl-phenyl-cyclohexanonderivate
MY127328A (en) 5-amino-1-pentene-3-ol substituted derivatives
WO2001070744A3 (en) Process for the preparation of midazolam
YU67203A (sh) Derivati caloporosida, postupak za njihovu proizvodnju i njihova primena
IN184757B (es)
MXPA04000953A (es) Derivados sustituidos del acido 5,6,6a,11b-tetrahidro-7-oxa-aza-benzo[c]fluoren-6-carboxilico como antagonista de nmda.
SE9901340D0 (sv) Novel process
TW200407314A (en) Preparation of 4, 6-dichloro-5-fluoropyrimidine